Q3 2024 EPS Estimates for DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Cut by William Blair

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Equities research analysts at William Blair dropped their Q3 2024 earnings per share estimates for DENTSPLY SIRONA in a research note issued on Wednesday, July 31st. William Blair analyst B. Vazquez now forecasts that the medical instruments supplier will post earnings per share of $0.48 for the quarter, down from their previous forecast of $0.51. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.99 per share. William Blair also issued estimates for DENTSPLY SIRONA’s FY2024 earnings at $1.98 EPS, Q1 2025 earnings at $0.54 EPS, Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.65 EPS and FY2025 earnings at $2.29 EPS.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Wednesday, July 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.01). The firm had revenue of $984.00 million during the quarter, compared to analyst estimates of $993.61 million. DENTSPLY SIRONA had a negative net margin of 4.75% and a positive return on equity of 11.86%. The company’s quarterly revenue was down 4.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.51 earnings per share.

A number of other research firms have also recently weighed in on XRAY. Evercore ISI lowered their price target on DENTSPLY SIRONA from $28.00 to $27.00 and set an “outperform” rating on the stock in a report on Tuesday, July 9th. Piper Sandler reaffirmed a “neutral” rating and issued a $32.00 target price (down from $35.00) on shares of DENTSPLY SIRONA in a research report on Friday, May 3rd. Stifel Nicolaus cut their target price on DENTSPLY SIRONA from $30.00 to $28.00 and set a “hold” rating on the stock in a research report on Thursday, July 18th. StockNews.com downgraded DENTSPLY SIRONA from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Finally, Barrington Research restated an “outperform” rating and set a $38.00 target price on shares of DENTSPLY SIRONA in a research note on Monday, July 8th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $33.44.

DENTSPLY SIRONA Stock Performance

Shares of XRAY stock opened at $25.49 on Friday. The stock has a market capitalization of $5.17 billion, a PE ratio of -57.93, a price-to-earnings-growth ratio of 1.28 and a beta of 1.01. DENTSPLY SIRONA has a 52-week low of $23.94 and a 52-week high of $40.92. The stock’s 50-day moving average price is $26.18 and its 200 day moving average price is $30.08. The company has a quick ratio of 0.97, a current ratio of 1.33 and a debt-to-equity ratio of 0.57.

Institutional Investors Weigh In On DENTSPLY SIRONA

Hedge funds have recently bought and sold shares of the company. Parkside Financial Bank & Trust boosted its holdings in shares of DENTSPLY SIRONA by 33.3% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,169 shares of the medical instruments supplier’s stock worth $42,000 after buying an additional 292 shares during the period. Wahed Invest LLC increased its position in DENTSPLY SIRONA by 9.3% during the 4th quarter. Wahed Invest LLC now owns 3,603 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 306 shares in the last quarter. VisionPoint Advisory Group LLC increased its position in DENTSPLY SIRONA by 57.1% during the 4th quarter. VisionPoint Advisory Group LLC now owns 1,216 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 442 shares in the last quarter. Raymond James Trust N.A. grew its holdings in DENTSPLY SIRONA by 4.9% during the 2nd quarter. Raymond James Trust N.A. now owns 9,658 shares of the medical instruments supplier’s stock worth $241,000 after acquiring an additional 453 shares during the last quarter. Finally, UMB Bank n.a. grew its holdings in DENTSPLY SIRONA by 0.6% during the 4th quarter. UMB Bank n.a. now owns 74,181 shares of the medical instruments supplier’s stock worth $2,640,000 after acquiring an additional 473 shares during the last quarter. 95.70% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Gregory T. Lucier purchased 3,577 shares of the firm’s stock in a transaction dated Friday, May 31st. The shares were acquired at an average cost of $27.95 per share, with a total value of $99,977.15. Following the completion of the purchase, the director now directly owns 58,374 shares of the company’s stock, valued at $1,631,553.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.52% of the company’s stock.

DENTSPLY SIRONA Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 11th. Shareholders of record on Friday, September 27th will be paid a dividend of $0.16 per share. The ex-dividend date of this dividend is Friday, September 27th. This represents a $0.64 annualized dividend and a yield of 2.51%. DENTSPLY SIRONA’s dividend payout ratio is -145.45%.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.